Interchangeable biosimilars 'within two years,' says FDA

The US Food and Drug Administration anticipates that interchangeable biosimilars will be available in the USA within two years.

Biosimilars lead Leah Christl made the observation at the Drug Information Association’s annual meeting in Chicago recently.

As The Regulatory Affairs Professionals Society reports, Dr Christl also confirmed that: “The first interchangeable biosimilar will likely be reviewed by an FDA advisory committee of outside experts.”